SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.40    -0.40 (-0.31%)
Bid:
127.60
Ask:
128.40
Spread: 0.80 (0.627%)
Market Cap: £534.67m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Trading Update

31 Jul 2024 07:00

RNS Number : 4227Y
James Halstead PLC
31 July 2024
 

 

31 July 2024

 

 

JAMES HALSTEAD PLC (the "Company")

Trading Update

James Halstead plc, the commercial flooring manufacturer and international distributor, is providing the following trading update ahead of its results for the year ended 30 June 2024.

 

The Company is fully confident of exceeding the prior year comparatives for profit, cash levels and dividend, with improved profitability seen in the first half continuing into H2.

 

The Company sells, for the most part, commercial flooring across the world and has seen continued confidence in the segment of resilient sheet flooring that is sold into the healthcare, education and other institutional sectors. Regionally sales into the Middle East and the Americas have been particularly buoyant. Some of the Company's products are focused on domestic sectors and performance of these products have been weaker in several territories - the UK and Europe being the most significant.

 

Notwithstanding this drag on performance the Group's productive output, gains on product mix and cost control of overheads have bolstered margins.

 

There have been gains on lower raw material pricing although energy costs, principally electricity, remain high. Notwithstanding the fall in raw materials costs during the year these input costs, in general, are around 50% ahead of June 2020 levels.

 

Operationally, the widely reported disruption to shipping in the Red Sea has lengthened delivery times and increased costs across the sector, which is particularly difficult for our APAC markets. As a result stock in transit has increased and in response we are holding stocks in the our overseas marketplaces at higher than normal levels.

 

 

In summary, profit before tax will be at record levels and in line with (upwardly revised) market expectations.

 

The Company expects to announce its results for the year ended 30 June 2024 on 1 October 2024.

 

 

The Company also announces that its Nominated Adviser and Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

 

 

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Chief Executive

Gordon Oliver, Finance Director

 

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon / Nick Moore

Panmure Liberum (Nomad and Joint Broker)

Tel: 020 7886 2500

Ed Mansfield / Tom Scrivens

Zeus (Joint Broker)

Ben Thorne / Fraser Marshall

 

Tel: 020 3829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKKBKDBKDDON
Date   Source Headline
6th Jun 20124:40 pmRNSSecond Price Monitoring Extn
6th Jun 20124:35 pmRNSPrice Monitoring Extension
1st Jun 20127:00 amRNSTotal Voting Rights
25th May 20122:00 pmRNSDirector/PDMR Shareholding
1st May 20127:00 amRNSTotal Voting Rights
2nd Apr 20123:45 pmRNSDirector/PDMR Shareholding
29th Mar 20127:00 amRNSInterim Results
12th Mar 20124:35 pmRNSPrice Monitoring Extension
1st Mar 20127:00 amRNSTotal Voting Rights
30th Jan 20127:00 amRNSPre-Close Trading Statement
11th Jan 20127:00 amRNSAppointment of Broker
4th Jan 20127:00 amRNSAppointment of non-executive director
3rd Jan 20127:00 amRNSBlocklisting Interim Review
3rd Jan 20127:00 amRNSTotal Voting Rights
6th Dec 20111:00 pmRNSDirector's shareholding
5th Dec 20114:45 pmRNSChange in shareholdings
2nd Dec 20117:00 amRNSAGM Statement
30th Nov 201110:50 amRNSResult of Tender Offer
14th Nov 20117:00 amRNSTender Offer and Trading Update
1st Nov 20117:00 amRNSTotal Voting Rights
28th Oct 20112:00 pmRNSAnnual Financial Report
11th Oct 201111:00 amRNSChange in Director's Holding
3rd Oct 20117:00 amRNSPreliminary Results
6th Sep 20117:00 amRNSNotice of Results
15th Aug 20117:00 amRNSTotal Voting Rights
26th Jul 20117:00 amRNSPre-close Trading Statement
6th Jul 20118:45 amRNSDirector/PDMR Shareholding
1st Jul 20117:00 amRNSBlocklisting Interim Review
3rd May 20117:00 amRNSTotal Voting Rights
15th Apr 20112:40 pmRNSDirector/PDMR Shareholding
1st Apr 20117:00 amRNSTotal Voting Rights
31st Mar 20117:00 amRNSInterim Results
31st Jan 20112:00 pmRNSHolding(s) in Company
31st Jan 20117:00 amRNSPre-close Trading Statement
13th Jan 20113:30 pmRNSIssue of Equity and Total Voting Rights
12th Jan 20119:30 amRNSBonus Issue
4th Jan 20119:45 amRNSTotal Voting Rights
4th Jan 20119:10 amRNSBlocklisting Interim Review
21st Dec 20103:45 pmRNSDirector/PDMR Shareholding
3rd Dec 20107:00 amRNSAnnual General Meeting
1st Nov 20107:00 amRNSTotal Voting Rights
25th Oct 20109:15 amRNSAnnual Report and Accounts
25th Oct 20109:15 amRNSAnnual Report and Accounts
30th Sep 20107:00 amRNSPreliminary Results
23rd Jul 20107:00 amRNSPre-Close Trading Update
1st Jul 20107:00 amRNSBlocklisting Interim Review
6th Apr 201012:00 pmRNSTotal Voting Rights
31st Mar 20104:17 pmRNSDirector/PDMR Shareholding
31st Mar 20107:00 amRNSInterim Results
1st Mar 20107:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.